Desitin Arzneimittel GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Desitin Arzneimittel GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10930
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Desitin Arzneimittel GmbH (Desitin) formerly Desitin Compagnie mbH, is a specialty pharmaceutical company which develops and produces products for the treatment of central nervous system (CNS) related neurological and psychiatric diseases. Its product portfolio includes antiepileptic drugs and antiparkinson medication. It offers medicines for illnesses such as Parkinson’s disease, epilepsy, dystonia, actinic keratosis, and post-stroke spasticity. Desitin also provides active pharmaceutical ingredients (APIs), besides manufacturing, clinical development, regulatory support, market access and health care services. It markets and distributes its products through a network of partner companies across Europe. The company has operations with offices in Denmark, Sweden, Norway, Czech Republic, Slovakia, Romania, Switzerland and the UK. Desitin is headquartered in Hamburg, Germany.

Desitin Arzneimittel GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 10
Biofrontera Enters Into Co-Marketing Agreement With Desitin For Ameluz 11
Licensing Agreements 12
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400 12
Advicenne Pharma Enters into Licensing Agreement with Desitin 13
Desitin Arzneimittel GmbH – Key Competitors 14
Desitin Arzneimittel GmbH – Key Employees 15
Desitin Arzneimittel GmbH – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Desitin Arzneimittel GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 10
Biofrontera Enters Into Co-Marketing Agreement With Desitin For Ameluz 11
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400 12
Advicenne Pharma Enters into Licensing Agreement with Desitin 13
Desitin Arzneimittel GmbH, Key Competitors 14
Desitin Arzneimittel GmbH, Key Employees 15
Desitin Arzneimittel GmbH, Subsidiaries 16

List of Figures
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Desitin Arzneimittel GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Desitin Arzneimittel GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genting Singapore Plc:戦略・SWOT・企業財務分析
    Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report Summary Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Banco del Pichincha CA:企業の戦略・SWOT・財務分析
    Banco del Pichincha CA - Strategy, SWOT and Corporate Finance Report Summary Banco del Pichincha CA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Roper Technologies Inc (ROP):企業の財務・戦略的SWOT分析
    Roper Technologies Inc (ROP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Birner Dental Management Services Inc (BDMS):企業の財務・戦略的SWOT分析
    Summary Birner Dental Management Services Inc (Perfect Teeth) is a dental care service provider. The company offers dental care services such as orthodontics, pediatric dentistry, periodontics, perio protect, endodontics and oral surgery. It also offers fillings and aesthetic procedures, porcelain v …
  • Veloxis Pharmaceuticals AS (VELO)-製薬・医療分野:企業M&A・提携分析
    Summary Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops therapies for kidney transplantation based on its proprietary MeltDose platform. MeltDose is a drug delivery technology, used to enhance oral bioavailability and control release of a drug. The company …
  • Acobiom:企業の製品パイプライン分析
    Summary Acobiom (Acobiom) is a biotechnology company that specializes in biomarker discovery and development of innovative diagnostics. The company undertakes the discovery of RNA and DNA biomarkers, which finds application in the areas of disease detection and classification, patient stratification …
  • IBIDEN CO., LTD.:企業の戦略・SWOT・財務情報
    IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Anixter International Inc.:企業の戦略・SWOT・財務情報
    Anixter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Anixter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • AstraZeneca AB-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca AB (AstraZeneca), a subsidiary of AstraZeneca Plc is a healthcare products provider that research and development of medicinal products. The company offers research and produces drug products in heart and cardiovascular, infection, cancer, metabolic diseases, respiratory, stomach …
  • ArmaGen Inc-製薬・医療分野:企業M&A・提携分析
    Summary ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a healthcare solution provide that discovers and develops novel therapies for the treatment of neurological disorders. The company's pipeline portfolio includes AGT-181, AGT-182, AGT-183 and AGT-184 which are used for the treatment …
  • Jones Soda Co.:企業の戦略・SWOT・財務情報
    Jones Soda Co. - Strategy, SWOT and Corporate Finance Report Summary Jones Soda Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ChanTest Corp-製薬・医療分野:企業M&A・提携分析
    Summary ChanTest Corp (ChanTest), a subsidiary of Charles River Laboratories International Inc is a contract research organization that discovers and develops drugs in ion channel and GPCR biology fields. The organization's ion channel products include cell lines and antibodies. Its other products c …
  • Antisense Therapeutics Ltd (ANP):製薬・医療:M&Aディール及び事業提携情報
    Summary Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on …
  • Medical Developments International Ltd (MVP)-製薬・医療分野:企業M&A・提携分析
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company’s products include penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products which inclu …
  • Aptuit LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aptuit LLC (Aptuit) is a provider of drug discovery and development services. The company offer wide range of services such as manufacturing, project management, small and large molecules analysis, formulation development, integrated chemistry, API route scouting and process development, con …
  • Kumiai Chemical Industry Co Ltd (4996):企業の財務・戦略的SWOT分析
    Summary Kumiai Chemical Industry Co Ltd (Kumiai Chemical) operates as a chemical company that develops, manufactures and markets agricultural chemicals, fine chemicals, and curing agents. The company's agricultural chemicals include bactericides, herbicides, fungicides, acaricides, microbial pestici …
  • Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include M …
  • Nisshinbo Holdings Inc. (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc. (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Life Insurance Corporation of India:企業の戦略的SWOT分析
    Life Insurance Corporation of India - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Acuity Brands Inc (AYI):企業の財務・戦略的SWOT分析
    Acuity Brands Inc (AYI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆